474 related articles for article (PubMed ID: 36889359)
21. Personalized neoantigen vaccine combined with PD-1 blockade increases CD8
Chen H; Li Z; Qiu L; Dong X; Chen G; Shi Y; Cai L; Liu W; Ye H; Zhou Y; Ouyang J; Cai Z; Liu X
J Immunother Cancer; 2022 Sep; 10(9):. PubMed ID: 36113894
[TBL] [Abstract][Full Text] [Related]
22. Spatial proteomics of immune microenvironment in nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Li M; Wang L; Cong L; Wong CC; Zhang X; Chen H; Zeng T; Li B; Jia X; Huo J; Huang Y; Ren X; Peng S; Fu G; Xu L; Sung JJY; Kuang M; Li X; Yu J
Hepatology; 2024 Mar; 79(3):560-574. PubMed ID: 37733002
[TBL] [Abstract][Full Text] [Related]
23. SRSF10 facilitates HCC growth and metastasis by suppressing CD8
Luo X; Zhang Z; Li S; Wang Y; Sun M; Hu D; Jiang J; Wang Y; Ji X; Chen X; Zhang B; Liang H; Li Y; Liu B; Xu X; Wang S; Xu S; Nie Y; Wu K; Fan D; Liu D; Huang W; Xia L
Int Immunopharmacol; 2024 Jan; 127():111376. PubMed ID: 38113691
[TBL] [Abstract][Full Text] [Related]
24. Targeting MS4A4A on tumour-associated macrophages restores CD8+ T-cell-mediated antitumour immunity.
Li Y; Shen Z; Chai Z; Zhan Y; Zhang Y; Liu Z; Liu Y; Li Z; Lin M; Zhang Z; Liu W; Guan S; Zhang J; Qian J; Ding Y; Li G; Fang Y; Deng H
Gut; 2023 Nov; 72(12):2307-2320. PubMed ID: 37507218
[TBL] [Abstract][Full Text] [Related]
25. Intrahepatic inflammatory IgA
Sung PS; Park DJ; Roh PR; Mun KD; Cho SW; Lee GW; Jung ES; Lee SH; Jang JW; Bae SH; Choi JY; Choi J; Ahn J; Yoon SK
J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35577505
[TBL] [Abstract][Full Text] [Related]
26. Huaier improves the efficacy of anti-PD-L1 Ab in the treatment of hepatocellular carcinoma by regulating tumor immune microenvironment.
Li H; You J; Wei Y; Zheng L; Yang J; Xu J; Li Y; Li Z; Yang X; Yi C
Phytomedicine; 2024 Jan; 123():155189. PubMed ID: 37984124
[TBL] [Abstract][Full Text] [Related]
27. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
Zhang W; Liu Y; Yan Z; Yang H; Sun W; Yao Y; Chen Y; Jiang R
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581055
[TBL] [Abstract][Full Text] [Related]
28. Single-cell RNA-sequencing atlas reveals an FABP1-dependent immunosuppressive environment in hepatocellular carcinoma.
Tang W; Sun G; Ji GW; Feng T; Zhang Q; Cao H; Wu W; Zhang X; Liu C; Liu H; Huang T; Liu L; Xia Y; Wang X
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38007237
[TBL] [Abstract][Full Text] [Related]
29. CRKL dictates anti-PD-1 resistance by mediating tumor-associated neutrophil infiltration in hepatocellular carcinoma.
Xie P; Yu M; Zhang B; Yu Q; Zhao Y; Wu M; Jin L; Yan J; Zhou B; Liu S; Li X; Zhou C; Zhu X; Huang C; Xu Y; Xiao Y; Zhou J; Fan J; Hung MC; Ye Q; Guo L; Li H
J Hepatol; 2024 Jul; 81(1):93-107. PubMed ID: 38403027
[TBL] [Abstract][Full Text] [Related]
30. LAIR1-mediated resistance of hepatocellular carcinoma cells to T cells through a GSK-3β/β-catenin/MYC/PD-L1 pathway.
Pan B; Ke X; Qiu J; Ye D; Zhang Z; Zhang X; Luo Y; Yao Y; Wu X; Wang X; Tang N
Cell Signal; 2024 Mar; 115():111039. PubMed ID: 38199599
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy-induced recruitment of myeloid-derived suppressor cells abrogates efficacy of immune checkpoint blockade.
Kwong TT; Wong CH; Zhou JY; Cheng ASL; Sung JJY; Chan AWH; Chan SL
JHEP Rep; 2021 Apr; 3(2):100224. PubMed ID: 33604533
[TBL] [Abstract][Full Text] [Related]
32. Blocking LTB
Yan J; Zhu J; Li X; Yang R; Xiao W; Huang C; Zheng C
Phytomedicine; 2023 Oct; 119():154968. PubMed ID: 37531900
[TBL] [Abstract][Full Text] [Related]
33. T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma.
Barsch M; Salié H; Schlaak AE; Zhang Z; Hess M; Mayer LS; Tauber C; Otto-Mora P; Ohtani T; Nilsson T; Wischer L; Winkler F; Manne S; Rech A; Schmitt-Graeff A; Bronsert P; Hofmann M; Neumann-Haefelin C; Boettler T; Fichtner-Feigl S; van Boemmel F; Berg T; Rimassa L; Di Tommaso L; Saeed A; D'Alessio A; Pinato DJ; Bettinger D; Binder H; John Wherry E; Schultheiss M; Thimme R; Bengsch B
J Hepatol; 2022 Aug; 77(2):397-409. PubMed ID: 35367533
[TBL] [Abstract][Full Text] [Related]
34. Target delivery of a PD-1-TREM2 scFv by CAR-T cells enhances anti-tumor efficacy in colorectal cancer.
Chen J; Zhu T; Jiang G; Zeng Q; Li Z; Huang X
Mol Cancer; 2023 Aug; 22(1):131. PubMed ID: 37563723
[TBL] [Abstract][Full Text] [Related]
35. Cancer cell-intrinsic STING is associated with CD8 + T-cell infiltration and might serve as a potential immunotherapeutic target in hepatocellular carcinoma.
Zhang Y; Zhai Q; Feng X; Chen D; Lu Y; Hu J; Xie H; Zhou L; Wu J; Zheng S
Clin Transl Oncol; 2021 Jul; 23(7):1314-1324. PubMed ID: 33502741
[TBL] [Abstract][Full Text] [Related]
36. Intratumoral PPT1-positive macrophages determine immunosuppressive contexture and immunotherapy response in hepatocellular carcinoma.
Weng J; Liu S; Zhou Q; Xu W; Xu M; Gao D; Shen Y; Yi Y; Shi Y; Dong Q; Zhou C; Ren N
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37385725
[TBL] [Abstract][Full Text] [Related]
37. IRE1α inhibition by natural compound genipin on tumour associated macrophages reduces growth of hepatocellular carcinoma.
Tan HY; Wang N; Tsao SW; Che CM; Yuen MF; Feng Y
Oncotarget; 2016 Jul; 7(28):43792-43804. PubMed ID: 27270308
[TBL] [Abstract][Full Text] [Related]
38. Isoformic PD-1-mediated immunosuppression underlies resistance to PD-1 blockade in hepatocellular carcinoma patients.
Tan Z; Chiu MS; Yang X; Yue M; Cheung TT; Zhou D; Wang Y; Chan AW; Yan CW; Kwan KY; Wong YC; Li X; Zhou J; To KF; Zhu J; Lo CM; Cheng AS; Chan SL; Liu L; Song YQ; Man K; Chen Z
Gut; 2023 Aug; 72(8):1568-1580. PubMed ID: 36450387
[TBL] [Abstract][Full Text] [Related]
39. Targeting OXCT1-mediated ketone metabolism reprograms macrophages to promote antitumor immunity via CD8
Zhu CX; Yan K; Chen L; Huang RR; Bian ZH; Wei HR; Gu XM; Zhao YY; Liu MC; Suo CX; Li ZK; Yang ZY; Lu MQ; Hua XF; Li L; Zhao ZB; Sun LC; Zhang HF; Gao P; Lian ZX
J Hepatol; 2024 May; ():. PubMed ID: 38759889
[TBL] [Abstract][Full Text] [Related]
40. Targeting inhibition of prognosis-related lipid metabolism genes including CYP19A1 enhances immunotherapeutic response in colon cancer.
Liu L; Mo M; Chen X; Chao D; Zhang Y; Chen X; Wang Y; Zhang N; He N; Yuan X; Chen H; Yang J
J Exp Clin Cancer Res; 2023 Apr; 42(1):85. PubMed ID: 37055842
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
